Compositions and methods for achieving immune suppression
AssigneeBeth Israel Deaconess Medical Center, Inc.
InventorsTerry B. Strom, Wlodzimierz Maslinski, Xin Xiao Zheng, Yon Su Kim, Sylvie Ferrari-Lacraz
Life of this patent
Estimating the term…
Abstract
Disclosed herein are therapeutic compositions containing agents that modulate the immune response in a patient.
Claims17
A therapeutic composition comprising a first agent that targets an interleukin-15 receptor (IL-15R), wherein the first agent comprises a mutant IL-15 polypeptide that inhibits at least one of the cellular events that normally occurs when wild-type IL-15 specifically binds to an IL-15 receptor complex, the mutant IL-15 polypentide comprising a mutation at position 149 and position 156 of SEQ ID NO:4,and a second agent that inhibits a costimulatory signal transmitted between a T cell and an antigen-presenting cell (APC), wherein the second agent comprises a polypeptide that binds CD28.
A method of suppressing an immune response in a patient, the method comprising administering to the patient a therapeutic composition comprising a first agent that targets an IL-15 R, wherein the first agent comprises a mutant IL-15 R, polypeptide that inhibits at least one of the cellular events that normally occurs when wild-type IL-15 specifically binds to an IL-15 receptor complex, the mutant IL-15 polypeptide comprising a mutation at position 149 and position 156 of SEO ID NO:4, and a second agent that inhibits a costimulatory signal transmitted between a T cell and an antigen presenting cell (APC), wherein the second agent comprises a polypeptide that binds CD28.
Dependencies are inferred from the claim text.